Prospective Evaluation of HIV Testing Technologies in a Clinical Setting: Protocol for Project DETECT
Authors:
- Joanne D SteklerJSJoanne D Stekler
- Lauren R VioletteLVLauren R Violette
- Hollie A ClarkHCHollie A Clark
- Sarah J McDougalSMSarah J McDougal
- Lisa A NiemannLNLisa A Niemann
- David A KatzDKDavid A Katz
- Pollyanna R ChavezPCPollyanna R Chavez
- Laura G WesolowskiLWLaura G Wesolowski
- Steven F EthridgeSESteven F Ethridge
- Vanessa M McMahanVMVanessa M McMahan
- Andy Cornelius-HudsonACAndy Cornelius-Hudson
- Kevin P DelaneyKDKevin P Delaney
Open Access
- 27 January 2020
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (1) , e16332
Abstract
Background: HIV testing guidelines provided by the Centers for Disease Control and Prevention (CDC) are continually changing to reflect advancements in new testing technology. Evaluation of existing and new point-of-care (POC) HIV tests is crucial to inform testing guidelines and provide information to clinicians and other HIV test providers. Characterizing the performance of POC HIV tests using unprocessed specimens can provide estimates for the window period of detection, or the time from HIV acquisition to test positivity, which allows clinicians and other HIV providers to select the appropriate POC HIV tests for persons who may be recently infected with HIV. Objective: This paper describes the protocols and procedures used to evaluate the performance of the newest POC tests and determine their sensitivity during early HIV infection. Methods: Project DETECT is a CDC-funded study that is evaluating POC HIV test performance. Part 1 is a cross-sectional, retrospective study comparing behavioral characteristics and HIV prevalence of the overall population of the Public Health–Seattle & King County (PHSKC) Sexually Transmitted Disease (STD) Clinic to Project DETECT participants enrolled in part 2. Part 2 is a cross-sectional, prospective study evaluating POC HIV tests in real time using unprocessed whole blood and oral fluid specimens. A POC nucleic acid test (NAT) was added to the panel of HIV tests in June 2018. Part 3 is a longitudinal, prospective study evaluating seroconversion sensitivity of POC HIV tests through serial follow-up testing. For comparison, HIV-1 RNA and HIV-1/HIV-2 antigen/antibody tests are also performed for participants enrolled in part 2 or 3. A behavioral survey that collects information about demographics, history of HIV testing, STD history, symptoms of acute HIV infection, substance use, sexual behaviors in the aggregate and with recent partners, and use of pre-exposure prophylaxis and antiretroviral therapy is completed at each part 2 or 3 visit. Results: Between September 2015 and March 2019, there were 14,990 Project DETECT–eligible visits (part 1) to the PHSKC STD Clinic resulting in 1819 part 2 Project DETECT study visits. The longitudinal study within Project DETECT (part 3) enrolled 27 participants with discordant POC test results from their part 2 visit, and 10 (37%) were followed until they had fully seroconverted with concordant positive POC test results. Behavioral survey data and HIV test results, sensitivity, and specificity will be presented elsewhere. Conclusions: Studies such as Project DETECT are critical for evaluating POC HIV test devices as well as describing characteristics of persons at risk for HIV acquisition in the United States. HIV tests in development, including POC NATs, will provide new opportunities for HIV testing programs. International Registered Report Identifier (IRRID): RR1-10.2196/16332Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Dramatic increase in preexposure prophylaxis use among MSM in King County, WashingtonAIDS, 2015
- Performance evaluation of the CHEMBIO DPP® (dual path platform) HIV-1/2 assay in early and established infectionsJournal of Clinical Virology, 2015
- SAMBA HIV Semiquantitative Test, a New Point-of-Care Viral-Load-Monitoring Assay for Resource-Limited SettingsJournal of Clinical Microbiology, 2014
- Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory CoastJournal of Clinical Virology, 2013
- A Two-Question Method for Assessing Gender Categories in the Social and Medical SciencesThe Journal of Sex Research, 2013
- Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blotJournal of Clinical Virology, 2013
- HIV Testing in a High‐Incidence Population: Is Antibody Testing Alone Good Enough?Clinical Infectious Diseases, 2009
- Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIVThe Journal of Infectious Diseases, 2004
- Dynamics of HIV viremia and antibody seroconversion in plasma donorsAIDS, 2003
- Clinical and Epidemiologic Features of Primary HIV InfectionAnnals of Internal Medicine, 1996